Table 4 Summary of results of the indirect comparison of CAB + RPV LA Q8W relative to SoC
Comparative effect measure (95% CI) | |||
|---|---|---|---|
Relative risk | Risk difference, % | Odds ratio | |
HIV-1 RNA < 50 copies/mL at Week 48 | 1.01 (0.95, 1.06) | 0.5 (− 4.40, 5.3) | 1.04 (0.49, 2.22) |
HIV-1 RNA ≥ 50 copies/mL at Week 48 | 1.10 (0.25, 4.90) | 0.2 (− 2.20, 2.60) | 1.10 (0.24, 5.03) |
CD4 cell count change from baseline, per μLa at Week 48 | – | − 5.1 (− 40.0, 29.7) | – |
No virologic data at Week 48 | 0.95 (0.42, 2.15) | − 0.7 (− 4.90, 3.60) | 0.94 (0.40, 2.24) |
Discontinuations due to AEs at Week 48 | 1.48 (0.40, 5.46) | 0.5 (− 2.5, 3.5) | 1.49 (0.39, 5.65) |
Any AE (excluding ISR) maintenance phase | 1.03 (0.94, 1.13) | 2.4 (− 4.90, 9.80) | 1.15 (0.69, 1.90) |
Serious AE (excluding ISR) maintenance phase | 1.73 (0.73, 4.11) | 2.4 (− 1.50, 6.3) | 1.78 (0.72, 4.40) |
Grade 3–5 AEs (excluding ISR) maintenance phase | 1.68 (0.78, 3.61) | 3.3 (− 1.3, 7.8) | 1.74 (0.77, 3.92) |
HIV-1 RNA < 50 copies/mL at Week 48 by baseline third active drug class | |||
INSTI | 1.04 (0.96, 1.13) | 3.8 (− 3.6, 11.2) | 1.62 (0.57, 4.60) |
NNRTI | 0.96 (0.89, 1.04) | − 4.0 (− 11.4, 3.3) | 0.50 (0.13, 1.99) |
PI | 1.01 (0.83, 1.24) | 1.0 (− 17.0, 19.1) | 0.96 (0.11, 8.12) |
HIV-1 RNA ≥ 50 copies/mL at Week 48 by baseline third active drug class | |||
INSTI | 1.03 (0.13, 7.97) | 0 (− 3.7, 3.7) | 1.03 (0.13, 8.27) |
NNRTI | 2.07 (0.08, 52.49) | 1.3 (− 2.2, 4.9) | 2.09 (0.08, 54.86) |
PIb | – | 1.1 (− 7.8, 10.0) | – |